Gossamer Bio, Inc. (GOSS)
8.39
-0.38
(-4.33%)
USD |
NASDAQ |
Oct 19, 16:00
8.48
+0.09
(+1.07%)
After-Hours: 16:13
Gossamer Bio Cash from Operations (Annual) : -171.27M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -171.27M |
| December 31, 2024 | -3.468M |
| December 31, 2023 | -159.16M |
| December 31, 2022 | -187.03M |
| December 31, 2021 | -188.89M |
| Date | Value |
|---|---|
| December 31, 2020 | -176.36M |
| December 31, 2019 | -144.83M |
| December 31, 2018 | -51.04M |
| December 31, 2017 | -5.745M |
| December 31, 2016 | 0.02M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| United Therapeutics Corp. | 1.561B |
| Arbutus Biopharma Corp. | -39.64M |
| Kura Oncology, Inc. | -64.06M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |